Abstract: Glaucoma is a serious and irreversibly blinding eye condition of public health importance in Africa. The absence of distinct early symptoms makes the condition hard to recognize by patients. The gradual vision deterioration that occurs is worse in one eye, thereby making it difficult for those affected to be aware of the vision loss until the advanced stages of the disease. We discuss the epidemiology of glaucoma in sub-Saharan Africa, highlighting the risk factors for the disease as well as risk factors for blindness in glaucoma patients. Available evidence suggests that treatment options of medical, surgical, and laser therapies for glaucoma are limited by availability of medicines and equipment, lack of adequate surgical and diagnostic skills, and high costs of treatment. We propose 3 complementary strategies in developing models of glaucoma care: strengthening clinical services for glaucoma; earlier detection of glaucoma in the clinics and communities; and strengthening health systems governance. Further research to define a suitable cost-beneficial treatment modality and mechanisms for financing eye care is required.
as the level of evidence used to define the disease varies with the resources and level of expertise of the personnel available for conducting the survey. Thus for population-based surveys, especially in resource-scarce settings, a definition of glaucoma was proposed by the International Society of Geographical and Epidemiological Ophthalmology, in that its diagnosis is made according to 3 levels of evidence, regardless of angle morphology. 1 Whatever the level of evidence or the type of survey used, it is important that both morphological damage and functional deficiencies in the eye are captured as accurately as possible, the best available resources following recommended guidelines such as the STROBE (Strengthening the Reporting of Observational studies in Epidemiology) for clarity of reporting. 2 The number of people with glaucoma worldwide was estimated to be 60.5 million in 2010; this will increase to almost 80 million by 2020. 3, 4 In a later review published in 2014, it was estimated that the number of people (aged 40-80 years) with glaucoma worldwide was 64.3 million, which would increase to 76.0 million in 2020 and 111.8 million in 2040. The global prevalence of all glaucoma for people aged 40 to 80 years was 3.5%; and the prevalence of primary open-angle glaucoma (POAG) in the same general population was highest in Africa at 4.2%.
There is a dearth of data on incidence of glaucoma in Africa. In Uganda, the all-cause incidence of blindness was 9.9/1000 person years, with glaucoma accounting for 3.6% of incident cases (ie, 0.36/1000 person years). 23 
RISK FACTORS FOR GLAUCOMA IN AFRICA
Primary open-angle glaucoma is the most common type of glaucoma worldwide 5 and among African patients, 5,7,24,25 accounting for up to 94 .5% 24 of all glaucoma types in prevalence surveys in Africans. African patients with POAG present with more advanced and rapidly progressive disease 25, 26 with associated blindness at presentation or soon after. 25, 27 As an important cause of irreversible blindness, 28 glaucoma is a disease of significant public health importance worldwide and especially in people of African descent. 13 The exact cause of POAG is unknown, but many risk factors have been identified. These known, and yet unknown, factors interact in a complex fashion to determine the development and progression of glaucoma. The majority of these risk factors are applicable to all patients with POAG from all regions of the world, however some are more peculiar to patients of African descent [29] [30] [31] and these somehow put them at a higher risk of developing glaucoma and developing blindness from it. Some of these factors may also pose management challenges that make us much more difficult to detect, diagnose, treat and follow-up glaucoma patients. An in-depth understanding of these risk factors will assist us in proffering viable solutions to the scourge of glaucoma blindness in Africa.
Ocular Factors
Raised intraocular pressure (IOP) is an important ocular risk factor with consistent and strong association with glaucoma development worldwide 27, 32 and among patients of African descent. 30, [32] [33] [34] [35] [36] [37] It continues to be the only modifiable factor in glaucoma treatment. [38] [39] [40] Higher levels of IOP were found among blacks in South Africa 41 and Canada, 42 compared with Caucasians in the same area. These 2 preceding studies 41,42 also found that patients of African descent had thinner corneas, and this has been associated with the development of POAG. 30 Other studies measuring central corneal thickness (CCT) showed thinner corneas among Africans.
9,43-45 This is of particular importance among African patients who already have higher pressures in general. The relationship between thin CCT and glaucoma risk (development and/ or progression) is probably not well understood but it may be that a thin cornea causes underestimation of the IOP measured using Goldman applanation tonometry. A correction factor is usually needed to get an accurate IOP in such patients. This underestimation may affect the target IOP, which may in turn lead to suboptimal and poor glaucoma control. 42, 46 Fluctuation in IOP is another important IOP-related factor which has also been investigated as a separate risk factor for glaucoma development. 47 Those prone to physiologically wide diurnal variations or patients who are not fully compliant with medical therapy may be particularly at risk.
Derivatives of IOP such as ocular perfusion pressure (OPP) 48, 49 and translaminar pressure gradient (TPG) 50-54 have also been explored to better understand their dynamics with glaucoma development, especially in patients with normal tension glaucoma. The optic nerve is exposed to intracranial pressure (ICP) in the subarachnoid space, and to IOP in the eye. The difference between the 2 pressure zones, as demarcated by the lamina cribrosa is referred to as the TPG (TPG = IOP -ICP). Lower mean OPP was found to be strongly associated with open-angle glaucoma (OAG) in Nigeria. 35 Perhaps future research into these relatively new risk factors will provide a better understanding of the pathogenesis and management strategies in glaucoma patients.
Other ocular risk factors that have been examined include optic disc abnormalities, 42,55,56 myopia, 57, 58 and corneal hysteresis. 59 Differences in the optic disc parameters (eg, large discs in Africans) 35, 42 between African and Caucasian should be taken into consideration when interpreting results from retinal nerve fiber layer and optic disc investigations. Such differences have been postulated to be responsible for some of the phenotypic variations among different races with glaucoma. 55, 60, 61 
Genetic Factors
The role of genetics in glaucoma has long been identified as important. 25, 27, 29, [62] [63] [64] Family members of glaucoma patients are at a higher risk of developing glaucoma [65] [66] [67] and have been recommended as the primary target of most screening programs. Saudi individuals of African origin are at a higher risk of developing POAG. 68 There are also differences among the many ethnic groups within the African continent. The Igbo and Mongo ethnic groups had higher prevalence figures in Nigeria  35 and Congo   37 respectively, lending credence to the importance of genetic factors. Furthermore, individuals with darker skin color were found to be more predisposed to developing glaucoma. 34, 69 Recent genetic studies, however, have yet to identify the role of well-known glaucoma gene variants among patients of African ancestry.
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Demographic Factors
The incidence and prevalence of glaucoma has been found to increase with age across all racial groups 7, 24, 27, 30, 35, 53, 66, 72, 73 and patients of African descent typically have the highest prevalence of OAG across all age-groups. 74 The prevalence of POAG was 3.7% among adults aged 40 to 49 years, and 14.6% among those aged 80 years and above in Ghana, 24 whereas a Nigeria study showed an increase from 9.7% to 16.7% between the 2 age-groups. 35 Many of the identified risk factors for glaucoma/POAG such as IOP, CCT, facility of outflow and other anatomically predisposing factors tend to change with age, 45,75-80 and might be responsible for this association, although there are many potentially confounding variables to consider. It is noteworthy that the majority of these long-term cohort studies were conducted among individuals of non-African descent, leaving an important gap in knowledge in this area.
The relationship between POAG and sex has been somewhat inconsistent in non-African patients with glaucoma and predilection findings vary from no association 29, 81 towards males, among Africans and people of African descent tend toward the male sex. 35, 66, 85 Clinic-based studies also showed a general male preponderance, 86- 88 and 72% in Tanzania. 89 Such male preponderance, however, may be due to better access to healthcare by males.
Low body mass index (BMI) has also been associated with POAG among patients of African descent in some population-based studies in the US, 91 Barbados, 66 and Nigeria (lower BMI was associated with 60% greater odds of OAG, P = 0.001 35 ) . A case-control study in Congo also found a weak association between BMI and risk of OAG with odds ratio (OR) of 1.09 [95% confidence interval (CI), 1.01-1.18; P = 0.05]. 67 It has been postulated that individuals with low BMI may have a low ICP with consequent high TPG leading to the development of POAG. 50, 52, 92 This warrants further research, especially among Africans who have a great burden of disease from POAG.
Systemic Factors
Systemic diseases such as hypertension and diabetes mellitus have been linked with the prevalence and incidence of POAG in African studies, 35, 93, 94 as well as studies among individuals of African descent 95, 96 residing in other regions of the world. A study among a black population in the UK found no associations of glaucoma with hypertension. 34 This may not be surprising owing to the non-uniform unit of measurements and definitions in different studies, and age was a confounding factor. 96 Higher systemic blood pressure is also related with OPP, which has been found to be associated with risk of POAG. 30, 96 Population-based studies among patients of African descent with open-angle glaucoma did not show any relationship with diabetes mellitus, 30, 35, 65, 66 and a cross-sectional study in London also revealed no such association. 34 However, some clinic-based studies indicated a positive association. 93, 95 A study also examined a possible association of glaucoma with onchocerciasis. 97 
Other Risk Factors
Lifestyle choices such as smoking have not shown consistent association with POAG among black populations, as some studies showed association 37, 98, 99 while others did not. 95 A study among African American women found that alcohol consumption was an independent risk factor for POAG. 99 
RISK FACTORS FOR GLAUCOMA BLINDNESS
Glaucoma is a blinding eye condition, and in Africa, blindness is a common presenting feature. The rate of progression to blindness varies and depends on many factors. The majority of people with glaucoma remain undiagnosed leading to unilateral or bilateral blindness at presentation. With the World Health Organization (WHO) definition of visual acuity of less than 3/60 in the better eye, the proportion of participants with glaucoma blindness was reported as 2.5% 24 and 20% 7 in 2 population-based studies. In some clinic-based studies in Africa, the proportion ranged from 15% to 52%, 86, 88 ,89,100,101 with a higher frequency of unilateral blindness. 19, 89, 100 Many of the risk factors associated with the development of glaucoma are also associated with the risk of blindness at presentation as well as progression of the disease. Older age is associated with higher risk of glaucoma blindness as reported by some studies among African descents. 19, 35, 87, 102 It is also associated with the risk of glaucoma progression. Although a study in Ghana 88 reported higher risk of blindness among younger patients, the study population included significant proportion (26%) of young individuals (<40 years of age), who might have juvenile forms of glaucoma known to present with very high IOP and higher risk of vision loss. Even though increasing age is a common risk factor for glaucoma blindness and progression among blacks and whites, blacks present with blindness much earlier and at a more severe stage. 29, 31, 103, 104 Severity of disease at presentation affects the rate of progression. [105] [106] [107] [108] [109] [110] Africans typically have a higher IOP compared with their Caucasian counterparts, 41,42 with consequent higher risk of blindness at presentation and progression. 102, 110 Lowering of IOP has been conclusively proven to reduce the risk of glaucomatous progression. 38, 111 Parameters of IOP such as peak IOP, mean IOP, and fluctuations in IOP also play important roles in risk of progression and blindness. 47, 106, 108, 110, 112, 113 Socio-economic factors and awareness about glaucoma are very important in glaucoma progression and blindness especially in the African patients. Late diagnosis, illiteracy, 35, 87 poor knowledge and awareness of glaucoma, 87 poor compliance with treatment and follow-up, inadequate access to care facilities, 87, 88 and use of ineffective alternative therapy contribute to the burden of glaucoma blindness in Africa. Population-based studies in Africa reported that a very high proportion of participants with glaucoma were unaware that they had the disease, with the proportion being 97%, 24 94%, 7 and 87%, 19 in Ghana, Nigeria, and South Africa respectively. A clinic-based study in Cameroon found that almost 80% had not been previously diagnosed at presentation. 114 Socioeconomic deprivation increased the odds of blindness in glaucoma by about 4 times (OR = 3.57; 95% CI, 1.46-8.72) in a Nigeria study, 115 whereas a UK study on association between deprivation and late presentation of glaucoma found that African-Caribbean ethnic status accounted for some of the association for late presentation of glaucoma. 116, 117 Male sex, 102, 115 ethnicity, 102,115 long duration of disease, presence of systemic hypertension, 115 and thin cornea 110 have all been associated with higher risk of blindness in glaucoma. In the Nigeria study, multivariate analysis adjusting for other factors of blindness from glaucoma showed about 5 times higher odds in males than in females, with higher marginal predicted probabilities of glaucoma blindness increasing with age. 115 The effects of other ocular parameters such as focal lamina cribrosa defects 118, 119 and peripapillary changes 107, 120, 121 are yet to be fully elucidated among Africans.
TREATMENT OF GLAUCOMA
The aim of glaucoma treatment is to preserve the patient's visual function and quality of life, and prevent further loss of vision. The available treatment options are medical, surgical and laser therapies, all primarily aimed at reducing the IOP. Major landmark glaucoma trials that guide treatment patterns were not conducted in Africa and therefore have limited direct applications in African populations. 38, [122] [123] [124] Although in sub-Saharan Africa most people with glaucoma initially present at advanced stage, Trabeculectomy is the gold-standard glaucoma surgery. It is effective in achieving lower IOP and reducing the need for anti-glaucoma medication. 127, 128 However, poor acceptance of surgery by the patients and lack of surgical proficiency are some of the reasons why trabeculectomy is not being offered as primary treatment for glaucoma. 129, 130 Selective laser trabeculoplasty (SLT) has promising results in Africans and Afro-Caribbeans with glaucoma, [131] [132] [133] [134] [135] and these results can be generalized across patient types. 136 In terms of complications, SLT was extremely safe and achieved good results in POAG, ocular hypertension, and other forms of glaucoma. 137 The procedure has varied success rates between 40% and 70% and has efficacy comparable to prostaglandin analogs (PGAs) monotherapy or different anti-glaucoma medications used in combination. 138, 139 Additionally, other forms of laser therapies such as transscleral diode laser cyclophotocoagulation and micropulse laser trabeculoplasty were reported to show good IOP control in POAG. 140, 141 Although there are no clinical trials comparing SLT with trabeculectomy in Africans eyes, lasers, especially SLT, are the future of glaucoma treatment in Africa. It is a safe, less-invasive, and more cost-effective procedure. 142 However, high cost of the SLT machine is the major limiting factor with only few centers equipped with the instrument in sub-Saharan Africa.
Management of glaucoma is best undertaken by a glaucoma specialist team. The conceptual optimal care pathway is for people with glaucoma to know about the condition, have access to care, accept treatment, and maintain treatment. 143 Hence, suspected cases are referred for confirmation and those diagnosed are for treatment and follow-up. Prompt referral is important in earlier identification of urgent cases and in reducing false-positive rates. 144 In sub-Saharan Africa, 80% or more of the population live in the rural areas, whereas majority of ophthalmologists live in the urban areas, 126, 145 making it difficult for rural residents to access appropriate or specialised care due to distance, availability of accompanying relatives, and age of the patients. Telemedicine could confer some solutions to these problems. In India, positive results have been demonstrated in the use of telemedicine. 145 
OBSTACLES AND CHALLENGES TO PROVIDING/OBTAINING CARE Challenges in Diagnosis
Late presentation of glaucoma is a common phenomenon in sub-Saharan Africa, 25, 85, 89, [146] [147] [148] There are no noticeable early symptoms for glaucoma that may prompt patients to seek an eye examination or treatment. This means that unless regular/periodic eye examinations are done, most patients are diagnosed with very advanced disease in one or both eyes. In a hospital-based study among newly diagnosed glaucoma patients, about half of them had never heard of the term "glaucoma" before. 86 Knowledge of glaucoma among the general public is also poor. In addition, such knowledge is frequently limited, incorrect, and outright misleading. 143 Abdull 149 opined that patients with glaucoma in the community usually think they have cataract, and because of this, they tend to wait until the cataract is "mature" before they seek treatment. When they present with significant vision loss due to glaucoma, it is often too late to reverse the damage. Regular media channels such as radio, television, and social media will go a long way in improving public knowledge and awareness. 149 It has been recommended that a term for glaucoma in the local language be developed for appropriate health education and promotion in various communities using easily understood local languages. 150 A very important aspect of late presentation is the poor access to care for the majority of African patients. Even when patients are aware of the disease and willing to seek care, they frequently do not go to the hospital first. The reasons include long distance from place of residence to the hospital, lack of accompanying persons, prohibitive costs of care, and attitude of health care worker in some instances. They also often resort to ineffective or harmful traditional remedies, which may further worsen their condition, in addition to causing delay in receiving proper treatment.
8,149,151,152
Even though glaucoma is a disease of significant public health concern, screening the entire population is not cost-effective, largely impracticable, and generally not advisable. 153 There is a need for development of simple screening tools and methods with low false positives and false negatives. 154, 155 Primary healthcare workers are often the first cadre of personnel in rural areas and may be able to use simple screening and diagnostic tools, if available. Many of them, however, are hardly trained in primary eye care.
Inefficient referral networks characterizing many African health systems also contribute to challenges in early diagnosis. Allied eye care workers such as optometrists, ophthalmic nurses, and even opticians come in contact with many patients who are either not referred at all or referred very late. People with presbyopia requiring reading glasses usually present to other eye care workers apart from ophthalmologists, and this can be a very good opportunity to screen for glaucoma.
A robust primary eye care system and a referral network need to be developed urgently. Those particularly at risk of developing glaucoma, especially first-degree relatives of glaucoma patients, and the elderly should be targeted at and encouraged to undertake an eye examination which could detect the disease in the early stages when they might still have useful vision.
Challenges in Treatment
The non-reversible nature of vision loss in glaucoma even with effective treatment poses a management dilemma in many instances. There is a poor understanding of this basic fact by many patients; a study in Nigeria revealed that 72.6% of patients thought vision loss from glaucoma is reversible. 86 This contributes to poor compliance with treatment and follow-up, hopping from one hospital to another, 143 and use of harmful alternative or traditional remedies.
The resources needed for effective glaucoma treatment are often lacking or grossly inadequate in many African settings. Human resource development is a key component of the Vision 2020 strategy. [156] [157] [158] [159] Human resources at all levels of care have been found to be far below recommendations by WHO for the number of glaucoma specialists, general ophthalmologists, ophthalmic nurses, optometrists, eye unit managers and counsellors. 158 Most African countries are lagging behind in the achievement of the recommended number of personnel for healthcare, especially eye care, 160, 161 at all levels of health care. 162 Integral to the human resources for eye care are biomedical engineers or instrument technicians, but they are grossly insufficient in many eye care settings in Africa. This has contributed a great deal to the equipment and technological challenges, and ultimately poorer services, including glaucoma diagnosis and care. 163, 164 Compounding this scenario is the inequitable distribution of available personnel, with all ophthalmologists in Nigeria, for example, in urban areas, leaving the rural areas devoid of adequate care. 126 International brain drain as qualified clinicians seek more remunerative practice opportunities in more developed regions has further reduced the number of available eye care personnel.
Furthermore, few opportunities for skill acquisition and continuous professional development have limited the options available for the care of glaucoma patients, especially in terms of surgical intervention. There are currently very few facilities for sub-specialist training in glaucoma in African countries. To be away from work and family for a prolonged period of time is a significant obstacle to subspecialist skill acquisition for most practitioners.
Eye care workers continue to face the challenge of nonexisting, inadequate, or nonfunctional equipment in their care of the glaucoma patients, especially in public-funded hospitals, 159, 162, 163 which are patronised by the populace, especially the poor. Basic instruments such as tonometers 159 and ophthalmoscopes 126 are also lacking. Availability of appropriate infrastructure and technology has been conservatively estimated at around 50% in many developing countries. 157 The majority of the equipment is expensive and often needs regular maintenance which may not be available in a resource-limited environment. They often break down with consequent interruption in the quality of care. Most of these instruments in glaucoma management are not manufactured locally and often need international support which increases the turnaround time and maintenance costs when the equipments malfunction. The establishment of purchase financing, local distributorship, and maintenance contracts with manufacturers may solve some of these issues. A very important aspect of services is the provision of low-vision services and equipment for the irreversibly blind glaucoma patients, which will improve their quality of life.
Treatment options for glaucoma include medical, surgical or laser interventions, each with many peculiar and important challenges. Affordability, availability, and patient compliance are very important obstacles in the medical treatment of glaucoma. Older age, advanced stage of glaucoma, nonaffordability of medication, and lengthier time of follow-up were factors identified for nonadherence in Ethiopian patients, 165 whereas higher level of education and less frequency of eye drops were associated with adherence. 166 Good adherence of anti-glaucoma medication is important in IOP control; thus, nonadherence may lead to progressive glaucomatous damage to the optic nerve head and deterioration of visual function.
Surgical treatment (trabeculectomy with the use of antifibrotic agent) has been recommended as the treatment of first choice for African patients, due to the inherent problems with medical therapy mentioned above. 24, [167] [168] [169] [170] A successful surgery is able to control IOP for many years, and thereby prevent deterioration in vision. It is, however, worrisome that glaucoma surgical outputs are low 25, 159 and many ophthalmologists are somehow reluctant to offer and perform trabeculectomy for glaucoma patients. 151 Yet this may not be a uniform phenomenon in all African countries or even within countries. Some of the reasons put forward for this low glaucoma surgical output include fear of vision wipe-out and other complications of surgery, possible failure of trabeculectomy, lack of adequate skills in the procedure, and low uptake of surgery by patients. Patients are often reluctant to undertake glaucoma surgery because of the fear and the fact that vision cannot be restored, possibility of losing remaining vision if surgery fails or when complications arise, possible need for repeated surgeries, and initial high cost of the operation. 170 As put forth by an ophthalmologist during an interview in a qualitative survey, "…it is a thankless job." 147 The majority of the participants in a Nigerian survey involving providers agreed that surgery should be offered to the patients early on. However, medical treatment with adequate monitoring is another plausible option in early cases for patients who are counselled to understand the disease, can afford the medicines, and will most likely attend regular follow-up. 148 Other surgical procedures such as insertion of artificial drainage shunts and stents are being explored in African patients 171 and may provide a viable option for glaucoma management; this may reverse the downward trend in glaucoma surgical output.
Although there is no current audit of number of laser machines in eye units in sub-Saharan Africa, laser treatments such as laser trabeculoplasty, micropulse, and transscleral cyclodiode treatments are often not generally available and affordable. Special training is also needed for their safe and effective use. Nevertheless, they also add to the options available for the management of glaucoma in African patients if these barriers can be minimised.
140,149
Challenges in Follow-Up and Monitoring
Lifelong monitoring is an integral part of glaucoma management, and lack of adequate follow-up can pose serious consequences for glaucoma patients on medical or surgical therapy. 159 Patients may not return for check-up if they have the impression that their symptoms have not improved, and therefore assume the treatments are not effective. Independent predictors of poor follow-up include poorer visual acuity at presentation and endstage glaucoma. 172 The reverse may also be true as patients may fail to return for follow-up if they feel they are much better, and therefore do not need further treatment. Long distance from hospital, economic implications of repeated consultations, and sometimes, poor attitude of health care workers may account for some loss to follow-up. Addressing and solving these issues will improve glaucoma monitoring, in addition to adopting active follow-up methods such as reminders using short messages and phone calls where necessary. 149 
FINANCING GLAUCOMA CARE
The WHO encapsulates universal health coverage as "ensuring that all people have access to needed health services (including prevention, promotion, treatment, rehabilitation and palliation) of sufficient quality to be effective while also ensuring that the use of these services does not expose the user the financial hardship." 173 Glaucoma is a chronic debilitating eye disease with lifelong financial implications, which could be an economic burden on patients. 143 There is a dearth of data on financing glaucoma care in sub-Saharan Africa, although a study in Nigeria suggests that the strategies to improve glaucoma management should include development of healthcare financing strategies through universal health coverage and health insurance schemes. 126 While health insurance is available in many countries, its uptake is not universal. Analyzing data from the national demographic health surveys of Ghana, Kenya, Nigeria and Tanzania revealed that the uptake of national health insurance was highest in Ghana (62% in females) and lowest in Nigeria (1% in females). 174 An unpublished study in Nigeria revealed that only 1 in 10 patients had treatment paid for by health insurance while the rest were by out-of-pocket (OOP) expenditure (Bello Shahir Umar, written communication, November 2018). Such expenditure refers to direct payment by the user (user fees) at the point of service. It is the least desirable method of payment for healthcare but continues to be the leading means of paying for glaucoma and other medical care in Africa. It restricts access to healthcare as only those with liquid funds can afford care. According to the WHO, a mean of 36% (range, 26-76%) of all health expenditure in sub-Saharan Africa is by OOP payment with the least developed countries having more than 50%. 175 Donor funding and funding from governments contribute substantially to glaucoma care in various parts of Africa. However, the proportion of expenditure on glaucoma care covered by government and funding partners is not known.
Costs in glaucoma care may be related to direct cost of treatment to the providers and the patients, as well as indirect costs borne by the patients and carers/accompanying persons.
Choice of Cost-Effective Treatment
A study in Finland found that the major source of cost in OAG treatment is medication, accounting for up to 74% of annual costs. 176 Studies in the US showed that at current prices for PGAs, laser trabeculoplasty may be a more cost-effective alternative, 177 in that SLT becomes less costly than most proprietary medications within 1 year, and less costly than generic latanoprost and generic timolol after 13 and 40 months, respectively. 178 Other studies have found various surgical interventions as more effective than medication in the long run. In the US when compared with medication alone, tubes and trabeculectomy operations were highly cost-effective. 179 In Ontario, Canada, over a projected period of 6 years, the Trabectome, iStent, and endocyclophotocoagulation may all offer modest cost savings versus the cost of glaucoma medication. 180 From the Brazilian public health perspective, non-penetrating deep sclerectomy was the most cost-effective treatment option when compared with maximum medical therapy with PGAs. 181 With the absence of information on which treatment options are most cost-effective in Africa, more research is needed.
Direct Costs
In a Ghana study of 3 referral facilities, cost of managing glaucoma is significantly associated with patient's age and income and is influenced by medical prescription. 182 The direct costs of medication (US$36,000) was about 7 times higher than the direct non-medication costs of surgery and tests (US$4500) for 84 glaucoma patients in 1 year. 182 Non-selective beta-blockers remain the most prescribed 182 and also inexpensive class of glaucoma medications. 183 Generally, more medications are prescribed than surgery done, and fixed combinations of medications are likely to be more cost-effective than non-fixed combinations.
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In Brazil, a study concluded that the most cost-effective option for early glaucoma was primary laser, followed by primary medications. In patients with moderate glaucoma, surgery provided the best cost-effectiveness ratio, followed by laser and medications. For patients with advanced glaucoma, surgery was the most cost-effective alternative (less expensive and presented almost the same effectiveness as medical therapy). Medical treatment was also cost-effective for advanced glaucoma. 185 A review of the clinical and health economic evidence for control of glaucoma in sub-Saharan Africa found that the mean annual cost of anti-glaucoma drugs was US$394, with a mean direct nonmedication cost of US$54 per year, and a mean surgical cost of US$283 per year. The greatest challenges to intervention were low per capita income levels and high glaucoma treatment costs. 186 In Mexico, patients' monthly average economic burden of glaucoma was highest on low-income earners (up to 61.5% of their income), whereas moderate-income patients spent 19.5% and high-income patients spent 7.9% of their monthly income. The study concluded that economic burden of glaucoma is substantial not only for health systems, but also for the family and the patient. 187 In India, another developing country, the expenditure on anti-glaucoma medications ranged from 0.3% in high-income group to 123% of their monthly gross income in low-income group (P < 0.0001). 188 A study in Nigeria reported that lowincome earners spent all their income, whereas middle-income earners spent about half of their monthly income on medical treatment for glaucoma while not accepting surgery, which was a cheaper option. 125 
Indirect Costs
Nondrug cost is a very important concern in the management of glaucoma. In India, indirect costs of glaucoma management such as traveling expense, hospital stay, and loss of wages of patients and accompanying persons due to absence of work ranged from 1.6% in high-income group to 137% of the monthly income in low-income group (P < 0.0001). 188 This is higher than the direct cost of the treatment mentioned above, and similar in developed countries. In the UK, complete lifetime direct healthcare costs of glaucoma treatment in a database of 1136 patients attending the glaucoma clinic at Glasgow Royal Infirmary showed that nondrug costs made up 66% of the lifetime costs, which is much more than the direct drug costs (34%). 189 In Denmark, drug costs were a little higher, accounting for 57% of the total cost. 190 Indirect costs borne by glaucoma patients in Africa include loss of productivity and earnings for both the patient and a caring family member along with transportation costs, accommodation and food while traveling to a clinic often far away in an urban centre.
Cost of Screening
Screening for glaucoma is one modality to get patients to the care pathway earlier, but studies have shown that screening at population level was not cost-effective. 153, 191, 192 The United States Preventive Services Task Force recommendation on screening for glaucoma concluded that the current evidence is insufficient to assess the balance of benefits and harms of screening for POAG in adults. 193 Therefore, more innovative ways other than invitation of first-degree relatives and opportunistic screening in adults with presbyopia need to be investigated.
Technologies such as noncontact tonometry, optical coherence tomography, and even visual field analysis can be carried out by technicians, with the results sent to experts for assessment. In the US, teleglaucoma demonstrated improved cost benefits with a 20% increase in ophthalmologist-referral rate; it reduced patient travel times by 61 hours and physician wait times by 30% in comparison to in-person examination. 194 Such a model in Africa will reduce the indirect costs associated with managing glaucoma.
ADVOCACY AND ENGAGEMENT WITH POLICYMAKERS
There has been a call for governments in sub-Saharan Africa to improve their investments in tackling avoidable blindness and scale up existing services. The coalition of non-governmental organizations and other civic organizations under the International Agency for the Prevention of Blindness is urged to lead the advocacy to improve the current status in this region. 195 The use of modern technology should be considered in advocacy to improve glaucoma care. Through database approach, organizations (eg, Academy for Educational Development) have demonstrated how scientific facts could be utilised to propose valuable interventions by sufficiently estimating cost and effectiveness. Such big data could be used to justify and amplify facts about glaucoma and blindness due to glaucoma in sub-Saharan Africa thereby creating more attention leading to policies that will generate funding. 195 One of the few advocacy programs we have in Africa is the "STOP Glaucoma in Sub-Saharan Africa" initiative, 196 which has 4 main pillars: building capacity, enhancing awareness, and improving glaucoma detection and management. This program is geared towards training of highly qualified glaucoma subspecialist leaders and concurrently building collaborative centers of excellence for glaucoma care throughout sub-Saharan Africa. 196 
DEVELOPING MODELS FOR GLAUCOMA CARE
In view of the current status of glaucoma care in Africa, we propose 3 complementary strategies to strengthen glaucoma care: (1) ensuring that patients who access care receive optimal treatment in the hospitals; (2) improving awareness of glaucoma and introducing clinic and community approaches for earlier detection of glaucoma; and (3) strengthening health systems governance. 197 Improving clinical care and treatment options for patients by developing models of care is very important, with training of eye care teams for better glaucoma diagnosis and management. For example, Kyari et al 126 noted that 46% of ophthalmologists interviewed in Nigeria felt they needed more training to improve their skills in early glaucoma diagnosis and surgery. Towards achieving Universal Eye Health as advocated by the WHO, improving service delivery for glaucoma also requires the provision of high-quality but low-price anti-glaucoma drugs from the pharmaceutical companies, thereby enabling adherence to glaucoma medication. 198 Additionally, improving glaucoma financing mechanisms other than OOP expenditure for treatment requires advocacy for inclusion of glaucoma medications and surgical treatment in health insurance programs. Furthermore, to achieve better glaucoma care, there is a need for ensuring availability of equipment necessary for diagnosis and treatment at tertiary centers; ensuring prompt referrals from the secondary level of care; and incorporating mechanisms for patient-centered care. Patient-centered care is to include glaucoma education and counseling, whole-person life-course approaches 199 to take care of other health conditions, low vision and rehabilitation services, centralized electronic medical records and personalized health records. Such records may help address the incomplete understanding of glaucoma by patients and adherence to medication and treatment. 200 Earlier detection of glaucoma can be encouraged through the use of community-based screening programs working in collaboration with cataract detection and surgical programs as well as screening of first-degree relatives of glaucoma patients. 201, 202 The World Glaucoma Association has initiated programs to encourage subspecialty glaucoma fellowship through the introduction of short-term (3 months) International Council of Ophthalmology (ICO) Glaucoma fellowships and incorporation of glaucoma management into existing programs at a communiqué passed at the end of its 1st Africa Glaucoma Summit in Ghana in 2010. 203 Simplified treatment guidelines, as well as basic diagnostic equipment needed in low-resource settings have been developed by the ICO 204 and can be adapted to suit our environment. The International Agency for the Prevention of Blindness also has an essential list for glaucoma which is a vital resource in guiding the inventory and investments for setting up a highquality glaucoma service delivery. 205 Further research is required to enhance evidence base for glaucoma management in sub-Saharan Africa. Priority areas include: defining optimal treatment modalities through randomized controlled trials; determining approaches to earlier detection of glaucoma; and developing and specifying clinical guidelines and protocols of management in the local context. Other areas of research required include determining mechanisms for financing eye care and chronic blinding eye diseases such as glaucoma; quality of life and treatment outcome studies; and innovative interventions such as teleglaucoma (distance collaboration), artificial intelligence for diagnosis, and deep learning models to predict progression.
CONCLUSION
The recent initiatives and actions towards glaucoma care in Africa are quite encouraging despite the high burden of blindness from it. Indeed, the Sustainable Development Goal number 3/8 emphasizes that no diseases should be excluded and no group of people should be left behind. 206 As glaucoma care teams are being trained, care facilities are being equipped, and awareness of the disease improves care-seeking behavior for earlier detection, we are assured of a paradigm shift that glaucoma treatment can be sustained and that blindness due to glaucoma is preventable in Africa.
